Actively Recruiting
Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)
Led by Dr. David Wasserstein · Updated on 2026-03-16
34
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
Sponsors
D
Dr. David Wasserstein
Lead Sponsor
S
Sunnybrook Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to see if people with knee osteoarthritis would be willing to comply and adhere to incorporating Recombinant Human Growth Hormone (rHGH), specifically Saizen Somatropin solution, into their treatment plan. Participants will be asked to: * Self-inject the treatment solution (placebo or somatropin) into the abdominal or gluteal area once per day for a total of 6 weeks. * Complete questionnaires related to their knee pain and activities of daily living. * Provide blood tests. * Complete various measurements including: circumference of thigh, calf, and abdomen; strength of thigh and knee; range of motion of both knees; and gait analysis.
CONDITIONS
Official Title
Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between 18 - 65 years old.
- Diagnosis of isolated knee osteoarthritis for greater than 6 months.
You will not qualify if you...
- Previous or pending major intra-articular or reconstructive surgery to the involved knee, including femoral/tibial osteotomies, ligament repair/reconstruction, or cartilage transplantation. Patients with remote (>1 year) diagnostic arthroscopy, arthroscopic debridement, meniscectomy, or meniscal repair may be allowed at investigators' discretion.
- Previous major trauma (including fracture, dislocation, open injury) to the involved knee or ipsilateral hip, knee, ankle, or hip. Patients with prior complete ligament tears are excluded; chronic partial thickness ligament tears or degenerative/complex meniscal tears (>6 months from injury) may be included at investigators' discretion.
- Recent (less than 6 months) intra-articular injection into the involved knee.
- High grade ligamentous knee injury.
- Known allergy to recombinant human growth hormone (rHGH) or reconstitutive solutions.
- BMI less than 20 or greater than 35.
- History of growth disorder of bones or connective tissue, type 1 or 2 diabetes, myopathy, cancer, endocrine disorder, severe hypertension (SBP > 180), or rheumatologic disorder.
- Pregnant, breastfeeding, or actively attempting to get pregnant.
- Currently on hypoglycemic therapy, oral estrogen, or glucocorticoid replacement therapy.
- Difficulty with self-injection schedule or other cognitive/functional limitations.
- Taken creatine within 7 days before baseline; may pause supplements and rescreen if interested.
- Taken anabolic steroids within 42 days before baseline; may pause supplements and rescreen if interested.
- Vital signs or routine bloodwork outside normal range.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
Research Team
D
Dr. David Wasserstein
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here